Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for ECC4703, a thyroid hormone receptor (THR) agonist. The study will assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and subjects with elevated LDL.
Clinical Trial Details
The Phase I trial will evaluate ECC4703’s profile in both healthy volunteers and individuals with high LDL levels. The drug targets THRβ in the liver, which plays a key role in reducing liver fat and lowering atherogenic lipids.
Drug Profile
ECC4703 is a β-selective, liver-targeting THR full agonist. Preclinical studies showed it outperformed partial agonists like MGL-3196 and demonstrated strong efficacy in models of non-alcoholic steatohepatitis (NASH) and dyslipidemia.
Company Background
Eccogene is a clinical-stage firm focused on developing translational medicine for metabolic and immune-related diseases. The FDA approval marks progress in its pipeline targeting liver disorders and lipid metabolism.-Fineline Info & Tech
